Skip to main content
. Author manuscript; available in PMC: 2013 Aug 6.
Published in final edited form as: J Immunol. 2011 Jan 19;186(4):2643–2654. doi: 10.4049/jimmunol.1002983

Figure 4.

Figure 4

CD19 mAb treatment impairs allograft-specific IgG production. C57BL/6–129 huCD19Tg mice were given control, CD20, or CD19 mAb 7 d before receiving a fully MHC-mismatched DBA/2 heterotopic cardiac allograft. (A) Allograft survival following control (n=5, dashed line), CD20 (n=4, solid line), or CD19 (n=4, heavy solid line) mAb treatment. (B) Serum was collected from mice in (A) 14 d after grafting and analyzed for DBA/2-specific IgM (top panels) and IgG (bottom panels) by indirect immunofluorescence staining with flow cytometry analysis. Flow cytometry histograms (left panels) show representative IgM and IgG staining of DBA/2-derived P815 cells with serum from control (dashed line), CD20 (solid line), and CD19 (heavy solid line) mAb-treated mice, and untransplanted naïve mice (shaded). Values (right panels) represent the MFI of stained cells from individual mice that received the indicated treatment. Horizontal bars indicate mean MFI values for each group. Significant differences between control and CD20 or CD19 mAb sample means, or between specified means, are indicated: *, p<0.05; **, p<0.01.